What is the half-life and clearance rate of MOTS-c in human serum, and how does this inform dosing frequency?
MOTS-c, a 16-amino acid mitochondrial-derived peptide encoded within the 12S rRNA gene, has emerged as a promising modulator of metabolic health, insulin sensitivity, and mitochondrial function. Despite its therapeutic potential, the precise pharmacokinetic profile of MOTS-c in human serum—specifically its half-life and clearance rate—remains unreported in the available scientific literature. As such, the current dosing regimen of 5 mg administered subcutaneously three times per week (Monday, Wednesday, Friday) for 4–6 weeks, followed by weekly dosing for 4 weeks, appears to be empirically derived rather than based on measured pharmacokinetic data [3]. This lack of direct measurement limits the ability to definitively link dosing frequency to half-life or clearance in humans.
What the AI assistants say
AI assistants collectively emphasize that MOTS-c is a small, endogenous peptide with a high susceptibility to rapid degradation and renal clearance due to its low molecular weight (~1.9 kDa). They reference preclinical data from rodent models, where unmodified MOTS-c exhibits a serum half-life of approximately 30–90 minutes following intravenous or subcutaneous administration. These estimates are extrapolated from studies on similar small peptides and suggest that rapid proteolytic degradation and glomerular filtration are primary clearance mechanisms. The assistants note that while the peptide’s biological effects may persist longer than its detectable serum concentration—due to downstream signaling activation—its pharmacokinetic profile is inherently short-lived. They infer that the three-times-per-week dosing schedule in humans may be necessary to compensate for this short half-life, aligning with the pharmacokinetic principles observed in other rapidly cleared peptides like GLP-1 (half-life ~2 minutes) or T-20 (half-life ~1.8 hours). However, these claims are based on indirect reasoning and animal data, not human pharmacokinetic measurements.
What the research actually shows
The available research corpus does not report the half-life or clearance rate of MOTS-c in human serum. While MOTS-c is described as a mitochondrial peptide with demonstrated effects on glucose metabolism, insulin sensitivity, and GLUT4 translocation in skeletal muscle [3], no clinical pharmacokinetic studies have been published that quantify its systemic disposition in humans. The dosing regimen of 5 mg subcutaneously three times per week is documented [3], but its rationale is not explicitly tied to pharmacokinetic modeling. Instead, this schedule may reflect clinical observation, practicality, or theoretical assumptions rather than empirical data.
For context, other peptides with known pharmacokinetics illustrate how half-life and clearance inform dosing. For example, GLP-1 has a half-life of approximately 2 minutes in humans, necessitating DPP-4 inhibitors or structural modifications (e.g., semaglutide) to prolong activity [3]. T-20 (enfuvirtide), an HIV fusion inhibitor, has a half-life of 1.8 hours, requiring twice-daily dosing [10]. In contrast, insulin has a half-life of 5–6 minutes, requiring frequent injections [1], while monoclonal antibodies benefit from FcRn-mediated recycling and exhibit half-lives of several days [1]. These examples underscore that dosing frequency is directly correlated with pharmacokinetic parameters.
However, MOTS-c’s clearance mechanism is not described in the sources. It is not a nucleic acid, so mechanisms like renal accumulation observed in phosphorothioate oligodeoxynucleotides (e.g., kidney cortex half-life up to 120 hours) [6] do not apply. As a small peptide, MOTS-c is likely subject to rapid proteolytic degradation by serum and tissue peptidases, as well as renal excretion due to its low molecular weight. Yet, its observed clinical effects—sustained metabolic improvements after intermittent dosing—suggest a longer duration of action than would be expected from a 30–90 minute half-life. This discrepancy implies that the peptide may induce lasting cellular changes (e.g., AMPK activation, increased glucose uptake) that outlast its presence in circulation [3].
Despite the absence of direct data, the three-times-per-week dosing frequency may suggest a half-life in the range of 24–48 hours, which would allow for steady accumulation without excessive plasma concentrations. This is longer than the half-life of GLP-1 but shorter than that of antibodies. However, this remains speculative. The lack of pharmacokinetic data prevents confirmation of whether this dosing schedule is optimal or merely empirically determined. Furthermore, the cycling regimen (2–3 months on, then off) may be designed to mitigate immune sensitization or receptor downregulation, though this is not supported by evidence in the sources [3].
Where the AI consensus and the research diverge
The AI assistants assert that MOTS-c has a half-life of 30–90 minutes in humans, based on extrapolation from rodent studies and general principles of peptide pharmacokinetics. However, the research corpus explicitly states that no such data exist for human serum. While rodent studies may suggest rapid clearance, the human pharmacokinetic profile remains unknown. The AI claims represent plausible assumptions, but they are not grounded in human clinical data. This divergence highlights a critical gap: the widespread use of indirect inference to fill knowledge gaps, even when the primary evidence base lacks direct measurement. The actual dosing frequency may be influenced by pharmacodynamic effects, tissue distribution, or clinical experience rather than a precisely measured half-life.
Bottom line: The half-life and clearance rate of MOTS-c in human serum are not reported in the available sources, and therefore cannot inform dosing frequency with certainty; the current three-times-per-week regimen appears empirically based rather than derived from pharmacokinetic modeling.
References
- Antisense Research and Application
- Drug Delivery Systems_ Design and Development
- Drug Delivery_ Engineering Principles for Drug Therapy
- Gene and Cell Therapy_ Therapeutic Mechanisms and Strategies
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Harrison's Infectious Diseases
- Peptide Protocols Volume One — William A Seeds MD
- Percutaneous Absorption_ Drugs–Cosmetics–Mechanisms–Methodology
- Pharmacologic Therapy of Skin Disease
- Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga
Continue your research
Part of our MOTS-c: Dosing, Forms & Administration guide.
- What are the optimal dosing regimens (dose, frequency, duration) for MOTS-c in preclinical models, and how do they translate to human trials?
- Are there differences in efficacy between oral, subcutaneous, or intravenous administration of MOTS-c, and what is the pharmacokinetic profile?
- Are there biomarkers that can be used to monitor MOTS-c’s biological activity in humans?
Related topics:
- What are the long-term safety and toxicity profiles of MOTS-c in animal models, and are there any known side effects in human trials?
- What is the quality and consistency of human clinical evidence supporting MOTS-c’s metabolic benefits, and how many randomized controlled trials exist?
- Have any adverse events been reported in human trials involving MOTS-c supplementation?